Protamine sulfate is a positive ionic peptide with anti-heparin activity. Protamine sulfate has strong alkaline groups, which combine with strongly acidic heparin in the body to form a stable compound, making heparin lose its anticoagulant ability.
|Solubility (25°C)||Water ≥ 40 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related Thrombopoietin/Thrombin Products|
Enoxaparine is a low molecular heparin that binds to antithrombin (AT) and accelerates its inhibition of factor Xa.Enoxaparine has a higher affinity for factor Xa than for thrombin, and its action on thrombin does not require HCII (heparin cofactor II).
TFLLRNPNDK-NH2 is a biological active peptide.
Avatrombopag maleate (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag maleate mimics the biological activities of TPO. Avatrombopag maleate increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag maleate is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A.
NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca2+ inward flow.
Napsagatran hydrate is a novel and specific thrombin inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.